Categories: News

Healthcare Venture Capital Firm Longitude Capital Promotes Brian Liu to Principal

MENLO PARK, Calif. and GREENWICH, Conn. and BOSTON, March 04, 2021 (GLOBE NEWSWIRE) — Longitude Capital, a leading healthcare venture capital firm that invests in biotechnology, medical technology and health solutions companies, today announced the promotion of Brian Liu to Principal.

Dr. Liu focuses on investments in biotechnology companies and currently serves as board observer at: Dascena, a health solutions company developing algorithms as predictive biomarkers for complex conditions like COVID-19 and sepsis; Talaris Therapeutics, a biotechnology company developing a cell therapy to improve clinical outcomes for living donor kidney transplant recipients; and Vera Therapeutics, a biotechnology company developing drug treatments for IgA nephropathy that recently announced its $80 million financing. Dr. Liu previously served as board observer at Inflazome, a biotechnology company that is developing small molecules to block harmful inflammation and which was acquired by Roche for an upfront payment of €380 million in 2020.

Dr. Liu joined Longitude Capital in 2018 from McKinsey & Company, where he was an Engagement Manager in the pharmaceuticals and medical products practice.

Managing Director and Co-founder Patrick Enright commented, “In his relatively short tenure, Brian has demonstrated strong teamwork and sector knowledge related to our biotechnology and health solutions investment practices. We feel fortunate to have Brian on our team as we work to identify and build the next wave of companies focused on bringing novel medicines, devices and health solutions to the marketplace.”

About Longitude Capital

Longitude Capital is a leading healthcare venture capital firm, that invests in transformative biotechnology, medical technology and health solutions companies seeking to improve clinical outcomes, enhance quality of life and drive efficiency of healthcare delivery. Founded in 2006, Longitude Capital invests in both privately held and publicly traded companies through a variety of investment approaches. Longitude Capital has offices in Menlo Park, CA, Greenwich, CT, and Boston, MA. For more information, including a complete listing of investments, please visit www.longitudecapital.com or LinkedIn.

Source: Longitude Capital

CONTACT: Contact Information

Maggie Jamison

Longitude Capital

650-854-5700

mjamison@longitudecapital.com

Staff

Recent Posts

2026 Payer IT Outsourcing Outlook: Outcome-Based Managed Services, Production-Grade GenAI Governance, and Vendor-Risk Enforcement

Black Book Research Q4 flash survey shows health plans shifting from effort-based sourcing to KPI-backed…

9 hours ago

Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy

CHICAGO, IL / ACCESS Newswire / December 24, 2025 / Healthcare investors have seen this…

12 hours ago

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon…

12 hours ago

PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

12 hours ago

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec.…

12 hours ago